The Native Antigen Company 2023 Southern Hemisphere flu season antigens

In February and September of each year, the World Health Organization (WHO) convenes with its network of advisors to decide on flu vaccine formulations for the Northern and Southern Hemispheres, respectively. To support ongoing vaccine reformulation programs, The Native Antigen Company develops season-specific antigens to support vaccine and diagnostic manufacturers.

The company has announced that haemagglutinin (HA) and neuraminidase (NA) antigens are now available to cover the 2023 Southern Hemisphere vaccine formulation. Available in multiple vial sizes and in bulk quantities, antigens can be used in a range of applications, including immunoassay development and as immunogens.

Expressed using Native Antigen’s VirtuE HEK293 expression system, the antigens are designed to exhibit proper glycosylation and folding. The latest haemagglutinin antigens feature C-terminal T4 foldon domains, stabilising them in their trimeric conformation to present more native-like conformational epitopes.